share_log

Evelo Biosciences | S-8 POS: S-8 POS

Evelo Biosciences | S-8 POS:员工福利计划证券登记(修正)

美股sec公告 ·  01/26 17:31
Moomoo AI 已提取核心信息
Evelo Biosciences, Inc., a biotechnology company based in Delaware, has filed Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on January 26, 2024, to deregister unsold securities under two previous registration statements. The affected securities were initially registered for the company's 2021 Employment Inducement Award Plan and its 2015 Stock Incentive Plan, 2018 Incentive Award Plan, and 2018 Employee Stock Purchase Plan. This move follows the company's board of directors' decision on November 21, 2023, to dissolve the company in accordance with the Delaware General Corporation Law, pending stockholder approval. The deregistration effectively terminates the offerings of securities under the specified registration statements and removes from registration any unsold securities as of the date of the amendment.
Evelo Biosciences, Inc., a biotechnology company based in Delaware, has filed Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on January 26, 2024, to deregister unsold securities under two previous registration statements. The affected securities were initially registered for the company's 2021 Employment Inducement Award Plan and its 2015 Stock Incentive Plan, 2018 Incentive Award Plan, and 2018 Employee Stock Purchase Plan. This move follows the company's board of directors' decision on November 21, 2023, to dissolve the company in accordance with the Delaware General Corporation Law, pending stockholder approval. The deregistration effectively terminates the offerings of securities under the specified registration statements and removes from registration any unsold securities as of the date of the amendment.
总部位于特拉华州的生物技术公司Evelo Biosciences, Inc. 已于2024年1月26日向美国证券交易委员会(SEC)提交了生效后第1号修正案,要求根据先前两份注册声明注销未售出的证券。受影响的证券最初注册了公司的2021年就业激励奖励计划及其2015年股票激励计划、2018年激励奖励计划和2018年员工股票购买计划。此举是在公司董事会于2023年11月21日决定根据特拉华州通用公司法解散公司之后采取的,尚待股东批准。撤销注册实际上终止了根据特定注册声明发行的证券,并将截至修订之日的任何未售出证券从注册中删除。
总部位于特拉华州的生物技术公司Evelo Biosciences, Inc. 已于2024年1月26日向美国证券交易委员会(SEC)提交了生效后第1号修正案,要求根据先前两份注册声明注销未售出的证券。受影响的证券最初注册了公司的2021年就业激励奖励计划及其2015年股票激励计划、2018年激励奖励计划和2018年员工股票购买计划。此举是在公司董事会于2023年11月21日决定根据特拉华州通用公司法解散公司之后采取的,尚待股东批准。撤销注册实际上终止了根据特定注册声明发行的证券,并将截至修订之日的任何未售出证券从注册中删除。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息